Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdatifan Bioequivalence and Food Effect Study in Healthy Adults
NCT07641881Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of casdatifan in renal cell carcinoma (RCC) (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Maximum observed concentration and Area under the concentration-time curve. Started May 2026; status: completed.
02
Drugs
casdatifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07641881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641881.